Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionEquitable Holdings, Inc.
Latest Disclosed Ownership3,464 shares
Latest Disclosed Value $ 1,564,758
Equitable Holdings, Inc. reports 59.63% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 15, 2026 - Equitable Holdings, Inc. filed a 13F-HR form disclosing ownership of 3,464 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $1,546,815 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 2,170 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 59.63% during the quarter. The current value of the position is $1,530,187 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,464 1,294 59.63 1,565 59.10 0.0088
2026-02-17 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,170 -390 -15.23 984 -1.90 0.0067
2025-11-14 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,560 323 14.44 1,003 0.70 0.0074
2025-08-15 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,237 85 3.95 996 -4.60 0.0082
2025-05-13 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,152 415 23.89 1,043 49.21 0.0099
2025-02-12 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,737 -220 -11.24 699 -23.19 0.0067
2024-11-14 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,957 318 19.40 910 18.49 0.0088
2024-08-14 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,639 147 9.85 768 23.27 0.0081
2024-05-14 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,492 85 6.04 624 8.92 0.0070
2024-02-13 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,407 41 3.00 573 20.42 0.0071
2023-11-14 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,366 30 2.25 475 1.06 0.0068
2023-08-15 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,336 -178 -11.76 470 -1.47 0.0068
2023-05-15 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,514 721 90.92 477 108.30 0.0076
2023-02-14 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 793 793 229 0.0040
2021-02-09 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -1,791 -100.00 0 -100.00
2020-11-13 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,791 19 1.07 487 -5.25 0.0126
2020-08-13 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,772 1,772 514 0.0148
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.